A sixty-seven-years-old woman came to surgery for wiring of a fractured mandible. She had a history of Parkinson's disease and rheumatoid arthritis. There was no history of ischaemic heart disease. Her cardiovascular system was normal except for mild hypertension. Pulse rate was 80 beats/min and regular, blood pressure was 160/100, and preoperative electrocardiogram was normal.
Treatment on admission was amantadine hydrochloride 100 mg twice daily, L-dopa 500 mg three times daily, and prednisone 5 mg each morning. The patient had been receiving L-dopa and amantadine hydrochloride therapy for one year. The last dose of L-dopa and amantadine hydrochloride was 18 hours before surgery. Her weight was 61 kg.
Premedication was pethidine 50 mg and atropine 0·6 mg given one hour preoperatively. Hydrocortisone 100 mg was given intravenously immediately prior to induction.
The patient's electrocardiogram was monitored with a Teledronic model HS3, using a backplate.
She was induced with thiopentone 125 mg, suxamethonium 100 mg and intubated. She was then ventilated manually with N 2 0l0 2 5 : 2 litres for four minutes, when she was allowed to breathe spontaneously N 2 0l0 2 2: 2 litres and halothane 1·5 per cent, using a Mark III Fluotec vaporizer. Approximately five minutes after halothane had been started frequent ectopic beats were seen, which appeared suddenly. They were multifocal ventricular ectopic beats at a frequency of one in two beats with runs of continuous ventricular ectopic beats. No alteration in the ST segment or any other abnormality was noted. Halothane was • M.B., B.S., Registrar in Anaesthetics.
immediately ceased, and she was ventilated with 100 per cent oxygen. Four doses of lignocaine 50 mg were given over the next 15 minutes and anaesthesia was continued with N 2 0l0 2 2 : 2 litres and pancuronium 3 mg. Blood pressure did not fall below 140 systolic during the procedure. A lignocaine infusion was started. She continued to show ectopic beats for several hours after surgery. Postoperative electrocardiogram was normal, cardiac enzymes were also normal.
DISCUSSION
I.-Dopa is a precursor in the catacholamine synthesis pathway and, whilst itself inactive, it is converted to dopamine, noradrenalin and adrenalin in the body. Administration of exogenous L-dopa bypasses the rate-limiting step in catacholamine synthesis and increases central nervous system as well as peripheral nervous system dopamine stores.
Cardiac arrhythmias as well as hypotension are known complications of L-dopa therapy (Breese and Prange 1971, Goldberg 1971) .
Arrhythmias are especially common when L-dopa therapy is first started, and are thought to be due in part to the increase in circulating noradrenalin which has been displaced from stores by dopamine. There is little doubt that L-dopa administration can cause ventricular arrhythmias, especially in the presence of a sensitizing agent like halothane. Parks et al. (1970) have produced ventricular arrhythmias in dogs under halothane anaesthesia by intravenous infusion of quite small doses -of L-dopa and have shown that these arrhythmias can be prevented by pretreatment with a dopa decarboxylase inhibitor.
The question, then. is not whether, but how soon prior to anaesthesia, L-dopa should be withdrawn.
This subject has been reviewed in an editorial (Goldberg 1971) . Briefly, Goldberg concludes that the cardiovascular effects of L-dopa are the result of the generation of dopamine, and that dopamine acts on three separate receptors in the cardiovascular system. Firstly, on the beta-adrenergic receptors in the myocardium both directly and by release of noradrenalin from storage sites. Secondly, dopamine acts on alpha-adrenergic receptors to cause vasoconstriction. Thirdly, dopamine acts on specific dopaminergic receptors to cause renal and mesenteric vasodilation. Lui et al. (1971) studied the effect of L-dopa on the noradrenalin stores in the rat heart and indicated that the half-life of L-dopa and its immediate metabolite dopamine is of the order of a few hours. Thus Goldberg (1971) feels that the continuation of L-dopa therapy up to the night prior to anaesthesia should not pose an anaesthetic hazard. Lui et al. (1971) have not encountered any cardiovascular complications during anaesthesia in their patients when L-dopa therapy was stopped the night before. Breese and Prange (1971) , however, showed that chronic administration of L-dopa to rats markedly reduced cardiac noradrenalin after 40 days' treatment, and it remained significantly depleted 24 hours after L-dopa was stopped. Tolerance seems to develop to the effects of L-dopa at the peripheral level after three months' continuous administration, and this tolerance does not appear to be caused by impaired responsiveness to catacholamines (Whitsett and Goldberg 1972) .
The mode of action of amantadine hydrochloride is not fully known. It has been suggested that it acts by releasing catacholamines from storage sites. It is an amine of cyclical structure. To date there has been no report of cardiac arrhythmias in patients receiving amantadine. An amantadine-dopamine interaction has been described by Grelak et al. (1970) , who found that an intravenous injection of amantadine causes a small pressor response, which is much amplified if the patient is pretreated with L-dopa.
In view of the literature, it seems unlikely that either L-dopa or amantadine was responsible for the ventricular arrhythmias observed in this case, since 18 hours had elapsed between the last doses and anaesthesia. However, the appearance of arrhythmias five minutes after halothane was introduced is suggestive of a halothane-catacholamine interaction. Hypoxia or hypercarbia were unlikely causes as the patient's ventilation was always adequate.
Perhaps some further investigations into the effect of chronic administration of L-dopa in combination with amantadine on body catacholamine levels are desirable. Furthermore, I was unable to find any investigations into the effects of chronic L-dopa administration on body adrenalin stores and circulating adrenalin levels, which may be more significant since adrenalin has a greater effect on the cardiac beta-receptors than either dopamine or noradrenalin.
